Psychotic syndrome associated with anti-Ca/ARHGAP26 and voltage-gated potassium channel antibodies

J Neuroimmunol. 2015 Sep 15:286:79-82. doi: 10.1016/j.jneuroim.2015.07.009. Epub 2015 Jul 22.

Abstract

Background: Antibodies to the Rho GTPase-activating protein 26 (ARHGAP26, GRAF1) (also termed anti-Ca) were first described in patients with cerebellar ataxia. However, ARHGAP26 is also expressed in some hippocampal neurons. Moreover, some of the previously reported patients showed cognitive and affective symptoms. It is unknown whether those symptoms reflected involvement of the limbic system or were part of the so-called cerebellar cognitive/affective syndrome.

Case report: Here, we report a newly diagnosed anti-Ca/ARHGAP26-IgG-positive patient who presented with recurrent psychotic symptoms but no cerebellar ataxia. In addition, low-titer acetylcholine receptor antibodies, voltage-gated potassium channel complex antibodies (but no LGI1 or CASPR2 antibodies) and anti-nuclear antibodies of unknown specificity were detected, suggesting a general autoimmune predisposition. Thymectomy revealed mild thymic nodular hyperplasia.

Conclusion: This case indicates that the clinical spectrum of ARHGAP26-related autoimmunity might be broader than expected. Studies on the prevalence of anti-Ca/ARHGAP26 in patients with suspected limbic encephalitis seem warranted.

Keywords: Anti-ARHGAP26; Anti-Ca; Anti-nuclear antibodies; CASPR2; Cerebellar ataxia; GRAF1; GTPase regulator associated with focal adhesion kinase; Kv1.1; Kv1.2; Kv1.7; LGI1; Limbic encephalitis; Oligophrenin 1-like protein; Psychosis; Rho GTPase-activating protein 26; Voltage-gated potassium channels.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies / metabolism*
  • Antipsychotic Agents / therapeutic use
  • Calcium / metabolism
  • Cerebellum / metabolism
  • Diazepam / therapeutic use
  • Female
  • GTPase-Activating Proteins / immunology*
  • Hippocampus / metabolism
  • Humans
  • Immunoglobulins / therapeutic use
  • Potassium Channels, Voltage-Gated / immunology*
  • Psychotic Disorders / drug therapy
  • Psychotic Disorders / genetics*
  • Psychotic Disorders / metabolism
  • Psychotic Disorders / pathology
  • Risperidone / therapeutic use

Substances

  • ARHGAP26 protein, human
  • Antibodies
  • Antipsychotic Agents
  • GTPase-Activating Proteins
  • Immunoglobulins
  • Potassium Channels, Voltage-Gated
  • Risperidone
  • Diazepam
  • Calcium